New Medicine - A Comprehensive Information and Consulting Service  
HOME PRODUCTS & SERVICES ORDER/INQUIRY PRESS RELEASES EMPLOYMENT CONTACT US

Future Oncology - Technology, Products, Markets, and Service Opportunities

* Requires Adobe Acrobat Reader

FUTURE ONCOLOGY - TECHNOLOGY, PRODUCTS, MARKETS, AND SERVICE OPPORTUNITIES IN THE CANCER FIELD

FUTURE ONCOLOGY
Volume 9 #1/2
May 31, 2007

MECHANISMS IN MALIGNANCY

THE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFr) PATHWAY IN CANCER
PART II - TARGET CANCER INDICATIONS AND TARGETING APPROACHES

ErbB RECEPTORS ASSOCIATION BY CANCER INDICATION

  • EPIDERMAL GROWTH FACTOR RECEPTOR (EGFr)
    • Colorectal Cancer
    • Head and Neck Cancer
    • Lung Cancer
    • Prostate Cancer
    • Ovarian Cancer
    • Brain Cancer
    • Breast Cancer
    • Pancreatic Cancer
  • HEr2/neu (HEr2, ErbB2)
    • Breast Cancer
    • Ovarian Cancer
    • Pancreatic Cancer
    • Osteosarcoma
    • Lung Cancer
    • Other Malignancies

  • HEr3 (ErbB3)
  • HEr4 (ErbB4)
  • EGFr VARIANT III (EGFrvIII

TARGETING ErbB RECEPTORS FOR THE TREATMENT OF CANCER

  • INTRACELLULAR TARGETING

    • Reversible and Irreversible Inhibitors
    • Specific, Dual, and Pan-ErbB Inhibitors
  • EXTRACELLULAR TARGETING
    • Naked Monoclonal Antibodies (MAb)
    • Bispecific MAb
    • Immunoconjugates
  • IMMUNOTHERAPIES/VACCINES USING ErbB AS ANTIGENS

MECHANISMS OF RESISTANCE AND TOXICITY

  • RESISTANCE
  • TOXICITY

MEETING COVERAGE

NEW TARGETS AND DELIVERY SYSTEMS
IN CANCER DIAGNOSIS AND TREATMENT

FROM THE MARCH 2007 CONFERENCE ORGANIZED
BY THE SIDNEY KIMMEL CANCER CENTER IN SAN DIEGO, CA

ADOPTIVE IMMUNOTHERAPY (AI)
  • Adoptive Transfer of IL-2-activated Natural Killer (NK) Cells

NOVEL DRUG DELIVERY FOR TUMOR TARGETING AND IMAGING

  • Biologic Agents as Delivery Vehicles
    • Cytokine-induced killer (CIK) Cells
  • Nanotechnology

INTEGRATING MOLECULAR TARGETS AND BIOMARKERS

  • Correlation of Apoptosis, p53, and Mitochondria

TARGETING THE TUMOR MICROENVIRONMENT

  • Vaccines
    • Legumain-based vaccines
  • Prodrugs
  • Peritumoral Acinar Tissue Imaging

IMAGING OF TUMORS

  • Proteomic Mapping and Imaging
  • Imaging of Signal Transduction Pathways
  • Imaging of Tumors/Microenvironment
  • Monitoring of Cyclooxygenase-2 (Cox-2) to Assess Tumor Progression

VECTORS

  • Pancreatic Cancer-specific Vector
  • Breast Cancer-specific Vector
  • Endostatin Prodrug
  • Viral-based Therapy for Multiple Myeloma
  • Targeted adn Shielded Adenovirus Vectors
  • Whole Cell Vaccines for Acute Myeloid Leukemia (AML)
  • Replication-competent Retroviral (RCR) Vectors


LIST OF EXHIBITS

Exhibit 1 - Potential Treatment Implication(s) of Selected Related EGFr Pathway Mutations

Exhibit 2 - EGFr Family Member Expression Rates (%) in Human Malignancies

Exhibit 3 - Epidermal Growth Factor (EGF) Receptor (EGFr) in Malignancy

Exhibit 4 - HEr2/neu (Her-2/neu) in Malignancy

Exhibit 5 - ErbB3 in Malignancy

Exhibit 6 - ErbB4 in Malignancy

Exhibit 7 - Epidermal Growth Factor Receptor Variant III (EGFrvIII) in Malignancy

Exhibit 8 - Selected EGFr Family Small Molecule Tyrosine Kinase Inhibitors (TKI)

Exhibit 9 - Selected ErbB Receptor-Based Immunotherapies/Vaccine Approaches


HOME | PRODUCTS & SERVICES | ORDER/INQUIRY | PRESS RELEASES | EMPLOYMENT | CONTACT US

NEW MEDICINE, INC.
PHONE: 949-830-0448   FAX: 949-830-0887